BrainsWay is an industry leader in the field of transcranial magnetic stimulation (TMS). BrainsWayâs flagship Deep TMS technology is a non-invasive, well-tolerated outpatient treatment, clinically proven to treat psychiatric and neurological conditions. BrainsWay has received FDA-clearance for both major depression (MDD) and obsessive compulsive disorder (OCD- De Novo) and is developing more applications outside of the US. The company also has approval in Japan and other Asian countries. BrainsWay continues to push the TMS envelope with multiple clinical studies and further research into novel indications. BrainsWay has an experienced business and development management team, as well as the backing of key scientific opinion leaders. BrainsWay was founded in 2003 and began trading on the NASDAQ in 2019 under the symbol BWAY. Source
No articles found.
aTyrâs mission is to translate newly discovered biological pathways to develop i...
aTyrâs mission is to translate newly discover...
Immuron Ltd is a publicly listed Australian biopharmaceutical company focused on o...
Immuron Ltd is a publicly listed Australian bio...
Count.It connects with wearable tracking devices and apps to power community fitne...
Count.It connects with wearable tracking device...
We are a vertically integrated commercial biopharmaceutical company that develops,...
We are a vertically integrated commercial bioph...
Precipio has built a platform designed to eradicate the problem of misdiagnosis by...
Precipio has built a platform designed to eradi...
IDEXX Laboratories, Inc. is a member of the S&P 500ÂŽ Index and is a leader in pet...
IDEXX Laboratories, Inc. is a member of the S&P...
Fonar Corporation, the MRI Specialistâ˘, is the worldâs leading developer and m...
Fonar Corporation, the MRI Specialistâ˘, is th...
Join the National Investor Network and get the latest information with your interests in mind.